Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility

BACKGROUND: Bendamustine hydrochloride (BND HCl) is indicated for first-line treatment of chronic lymphocytic leukemia (CLL) and rituximab-refractory indolent non-Hodgkin lymphoma (iNHL). There are two ready-to-dilute (RTD) formulations of BND HCl on the US market: a large-volume, long-duration infu...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Elizabeth, Trautman, Holly, Thompson, Stephen, Ribalov, Rinat, Choudhry, Azhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997603/
https://www.ncbi.nlm.nih.gov/pubmed/33790596
http://dx.doi.org/10.2147/CEOR.S297284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997603/
https://www.ncbi.nlm.nih.gov/pubmed/33790596
http://dx.doi.org/10.2147/CEOR.S297284

Ejemplares similares